Evidence map›Paper›PMID 32761235›Full record

ArticleBlood advances2020

American Society of Hematology 2020 guidelines for treating newly diagnosed acute myeloid leukemia in older adults.

Mikkael A Sekeres, Gordon Guyatt, Gregory Abel, Shabbir Alibhai, Jessica K Altman, Rena Buckstein, Hannah Choe, Pinkal Desai, Harry Erba, Christopher S Hourigan and 13 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Blood advances, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 109 papers, 8 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
109citing papers in PubMed, 8 pooled it
15.3field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

109 citing papers in PubMed, 8 syntheses or guidelines pooled it, 180 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Trial
  10. Randomized Phase III SIERRA Trial ofJournal of clinical oncology : official journal of the American Society of Clinical Oncology · 2025
    Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. FDA Approval Summary: Oral Azacitidine for Continued Treatment of Adults with Acute Myeloid Leukemia Unable to Complete Intensive Curative Therapy.Clinical cancer research : an official journal of the American Association for Cancer Research · 2022
    Trial
  18. Trial
  19. Article
  20. Article

49 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

23 authors at 16 institutions in 4 countries.

Mikkael A SekeresLeukemia Program, Taussig Cancer Center, Cleveland Clinic, Cleveland, OH.
Gordon GuyattDepartment of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, ON, Canada.
Gregory AbelLeukemia Division, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.
Shabbir AlibhaiInstitute of Medical Sciences, Department of Medicine, University of Toronto, Toronto, ON, Canada.
Jessica K AltmanDepartment of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL.
Rena BucksteinOdette Cancer Centre, Division of Medical Oncology and Hematology, Department of Medicine, Sunnybrook Health Sciences Centre, Toronto, ON, Canada.
Hannah ChoeDivision of Hematology, The Ohio State University Comprehensive Cancer Center, Columbus, OH.
Pinkal DesaiDivision of Hematology and Medical Oncology, Weill Cornell Medicine, New York, NY.
Harry ErbaDepartment of Medicine, School of Medicine, Duke University, Durham, NC.
Christopher S HouriganNational Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD.
Thomas W LeBlancDepartment of Medicine, School of Medicine, Duke University, Durham, NC.
Mark LitzowDivision of Hematology, Mayo Clinic, Rochester, MN.
Janet MacEachernGrand River Regional Cancer Centre, Kitchener, ON, Canada.
Laura C MichaelisDivision of Hematology and Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI.
Sudipto MukherjeeLeukemia Program, Taussig Cancer Center, Cleveland Clinic, Cleveland, OH.
Kristen O'DwyerDivision of Hematology/Oncology, Department of Medicine, University of Rochester, Rochester, NY.
Ashley RoskoDivision of Hematology, The Ohio State University Comprehensive Cancer Center, Columbus, OH.
Richard StoneLeukemia Division, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.
Arnav AgarwalDepartment of Internal Medicine, University of Toronto, Toronto, ON, Canada.
L E Colunga-LozanoDepartment of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, ON, Canada.
Yaping ChangDepartment of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, ON, Canada.
QiuKui HaoDepartment of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, ON, Canada.
Romina Brignardello-PetersenDepartment of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, ON, Canada.
Impact · CACleveland Clinic · USDana-Farber Cancer Institute · USDuke University · USThe Ohio State University · USUniversity of Toronto · CACornell University · USGrand River Hospital · CAMayo Clinic in Arizona · USMedical College of Wisconsin · USNational Institutes of Health · USNorthwestern University · USSichuan University · CNSunnybrook Health Science Centre · CAUniversidad de Guadalajara · MXUniversity of Rochester · US

Funding

Detection, prevention and treatment of acute myeloid leukemia (AML) relapse.ZIAHL006163 · NHLBI · NATIONAL HEART, LUNG, AND BLOOD INSTITUTE · PI HOURIGAN, CHRISTOPHER · 2013 to 2023
$21.0M
6 · The paper itself

Abstract

backgroundOlder adults with acute myeloid leukemia (AML) represent a vulnerable population in whom disease-based and clinical risk factors, patient goals, prognosis, and practitioner- and patient-perceived treatment risks and benefits influence treatment recommendations.

objectiveThese evidence-based guidelines of the American Society of Hematology (ASH) are intended to support patients, clinicians, and other health care professionals in their decisions about management of AML in older adults.

methodsASH formed a multidisciplinary guideline panel that included specialists in myeloid leukemia, geriatric oncology, patient-reported outcomes and decision-making, frailty, epidemiology, and methodology, as well as patients. The McMaster Grading of Recommendations Assessment, Development and Evaluation (GRADE) Centre supported the guideline-development process, including performing systematic evidence reviews (up to 24 May 2019). The panel prioritized clinical questions and outcomes according to their importance to patients, as judged by the panel. The panel used the GRADE approach, including GRADE's Evidence-to-Decision frameworks, to assess evidence and make recommendations, which were subject to public comment.

resultsThe panel agreed on 6 critical questions in managing older adults with AML, mirroring real-time practitioner-patient conversations: the decision to pursue antileukemic treatment vs best supportive management, the intensity of therapy, the role and duration of postremission therapy, combination vs monotherapy for induction and beyond, duration of less-intensive therapy, and the role of transfusion support for patients no longer receiving antileukemic therapy.

conclusionsTreatment is recommended over best supportive management. More-intensive therapy is recommended over less-intensive therapy when deemed tolerable. However, these recommendations are guided by the principle that throughout a patient's disease course, optimal care involves ongoing discussions between clinicians and patients, continuously addressing goals of care and the relative risk-benefit balance of treatment.

Indexed as

HematologyLeukemia, Myeloid, AcuteVenous ThromboembolismAgedEvidence-Based MedicineHumansUnited States

Identifiers

PMID32761235
PMCPMC7422124
OpenAlexW3047569349

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.